000014678 001__ 14678
000014678 005__ 20180208202105.0
000014678 0247_ $$2pmid$$apmid:21153408
000014678 0247_ $$2DOI$$a10.1007/s00259-010-1690-z
000014678 0247_ $$2WOS$$aWOS:000288255500016
000014678 0247_ $$2ISSN$$a1432-105X
000014678 037__ $$aPreJuSER-14678
000014678 041__ $$aeng
000014678 082__ $$a610
000014678 084__ $$2WoS$$aRadiology, Nuclear Medicine & Medical Imaging
000014678 1001_ $$0P:(DE-Juel1)VDB65285$$aFloeth, F.W.$$b0$$uFZJ
000014678 245__ $$aComparison of (18)F-FET PET and 5-ALA fluorescence in cerebral gliomas
000014678 260__ $$aHeidelberg [u.a.]$$bSpringer-Verl.$$c2011
000014678 300__ $$a731 - 741
000014678 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article
000014678 3367_ $$2DataCite$$aOutput Types/Journal article
000014678 3367_ $$00$$2EndNote$$aJournal Article
000014678 3367_ $$2BibTeX$$aARTICLE
000014678 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000014678 3367_ $$2DRIVER$$aarticle
000014678 440_0 $$09906$$aEuropean Journal of Nuclear Medicine and Molecular Imaging$$v38$$x1619-7070$$y4
000014678 500__ $$3POF3_Assignment on 2016-02-29
000014678 500__ $$aThe authors wish to thank Suzanne Schaden and Elisabeth Theelen for assistance in the PET studies; Silke Grafmuller, Erika Wabbals and Sascha Rehbein for radiosynthesis of <SUP>18</SUP>F-FET. This work was supported by the Brain Imaging Center West (BICW).
000014678 520__ $$aThe aim of the study was to compare presurgical (18)F-fluoroethyl-L: -tyrosine ((18)F-FET) uptake and Gd-diethylenetriaminepentaacetic acid (DTPA) enhancement on MRI (Gd) with intraoperative 5-aminolevulinic acid (5-ALA) fluorescence in cerebral gliomas.(18)F-FET positron emission tomography (PET) was performed in 30 patients with brain lesions suggestive of diffuse WHO grade II or III gliomas on MRI. PET and MRI data were coregistered to guide neuronavigated biopsies before resection. After oral application of 5-ALA, 38 neuronavigated biopsies were taken from predefined tumour areas that were positive or negative for (18)F-FET or Gd and checked for 5-ALA fluorescence. (18)F-FET uptake with a mean tumour to brain ratio ≥1.6 was rated as positive.Of 38 biopsies, 21 corresponded to high-grade glioma tissue (HGG) of WHO grade III (n = 19) or IV (n = 2) and 17 biopsies to low-grade glioma tissue (LGG) of WHO grade II. In biopsies corresponding to HGG, (18)F-FET PET was positive in 86% (18/21), but 5-ALA and Gd in only 57% (12/21). A mismatch between Gd and 5-ALA was observed in 6 of 21 cases of HGG biopsy samples (3 Gd-positive/5-ALA-negative and 3 Gd-negative/5-ALA-positive). In biopsies corresponding to LGG, (18)F-FET was positive in 41% (7/17), while 5-ALA and Gd were negative in all but one instance. All tumour areas with 5-ALA fluorescence were positive on (18)F-FET PET.There are differences between (18)F-FET and 5-ALA uptake in cerebral gliomas owing to a limited sensitivity of 5-ALA to detect tumour tissue especially in LGG. (18)F-FET PET is more sensitive to detect glioma tissue than 5-ALA fluorescence and should be considered as an additional tool in resection planning.
000014678 536__ $$0G:(DE-Juel1)FUEK255$$2G:(DE-HGF)$$aNeurowissenschaften$$cL01$$x0
000014678 588__ $$aDataset connected to Web of Science, Pubmed
000014678 65320 $$2Author$$aCerebral glioma
000014678 65320 $$2Author$$aAmino acid PET
000014678 65320 $$2Author$$a[F-18] Fluoroethyl-L-tyrosine (F-18-FET)
000014678 65320 $$2Author$$a5-Aminolevulinic acid (5-ALA)
000014678 65320 $$2Author$$aFluorescence-guided resection
000014678 65320 $$2Author$$aGd-DTPA enhancement
000014678 650_2 $$2MeSH$$aAdult
000014678 650_2 $$2MeSH$$aAged
000014678 650_2 $$2MeSH$$aAminolevulinic Acid: metabolism
000014678 650_2 $$2MeSH$$aBlood-Brain Barrier: metabolism
000014678 650_2 $$2MeSH$$aBrain Neoplasms: metabolism
000014678 650_2 $$2MeSH$$aBrain Neoplasms: pathology
000014678 650_2 $$2MeSH$$aBrain Neoplasms: radionuclide imaging
000014678 650_2 $$2MeSH$$aFemale
000014678 650_2 $$2MeSH$$aGadolinium DTPA: diagnostic use
000014678 650_2 $$2MeSH$$aGlioma: metabolism
000014678 650_2 $$2MeSH$$aGlioma: pathology
000014678 650_2 $$2MeSH$$aGlioma: radionuclide imaging
000014678 650_2 $$2MeSH$$aHumans
000014678 650_2 $$2MeSH$$aMagnetic Resonance Imaging
000014678 650_2 $$2MeSH$$aMale
000014678 650_2 $$2MeSH$$aMiddle Aged
000014678 650_2 $$2MeSH$$aPositron-Emission Tomography
000014678 650_2 $$2MeSH$$aSpectrometry, Fluorescence
000014678 650_2 $$2MeSH$$aTyrosine: analogs & derivatives
000014678 650_2 $$2MeSH$$aTyrosine: diagnostic use
000014678 650_7 $$00$$2NLM Chemicals$$a(18F)fluoroethyltyrosine
000014678 650_7 $$0106-60-5$$2NLM Chemicals$$aAminolevulinic Acid
000014678 650_7 $$055520-40-6$$2NLM Chemicals$$aTyrosine
000014678 650_7 $$080529-93-7$$2NLM Chemicals$$aGadolinium DTPA
000014678 650_7 $$2WoSType$$aJ
000014678 7001_ $$0P:(DE-HGF)0$$aSabel, M.$$b1
000014678 7001_ $$0P:(DE-HGF)0$$aEwelt, C.$$b2
000014678 7001_ $$0P:(DE-HGF)0$$aStummer, W.$$b3
000014678 7001_ $$0P:(DE-HGF)0$$aFelsberg, J.$$b4
000014678 7001_ $$0P:(DE-HGF)0$$aReifenberger, G.$$b5
000014678 7001_ $$0P:(DE-HGF)0$$aSteiger, H.J.$$b6
000014678 7001_ $$0P:(DE-Juel1)131627$$aStoffels, G.$$b7$$uFZJ
000014678 7001_ $$0P:(DE-Juel1)131816$$aCoenen, H.H.$$b8$$uFZJ
000014678 7001_ $$0P:(DE-Juel1)131777$$aLangen, K.J.$$b9$$uFZJ
000014678 773__ $$0PERI:(DE-600)2098375-X$$a10.1007/s00259-010-1690-z$$gVol. 38, p. 731 - 741$$n4$$p731 - 741$$q38<731 - 741$$tEuropean Journal of Nuclear Medicine and Molecular Imaging$$v38$$x1619-7070$$y2011
000014678 8567_ $$uhttp://dx.doi.org/10.1007/s00259-010-1690-z
000014678 909CO $$ooai:juser.fz-juelich.de:14678$$pVDB
000014678 9141_ $$y2011
000014678 915__ $$0StatID:(DE-HGF)0010$$2StatID$$aJCR/ISI refereed
000014678 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR
000014678 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000014678 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000014678 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000014678 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000014678 9131_ $$0G:(DE-Juel1)FUEK255$$bLeben$$kL01$$lFunktion und Dysfunktion des Nervensystems$$vNeurowissenschaften$$x0
000014678 9132_ $$0G:(DE-HGF)POF3-579H$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$vAddenda$$x0
000014678 9201_ $$0I:(DE-Juel1)INM-4-20090406$$gINM$$kINM-4$$lPhysik der Medizinischen Bildgebung$$x0
000014678 9201_ $$0I:(DE-Juel1)INM-5-20090406$$kINM-5$$lNuklearchemie$$x1
000014678 970__ $$aVDB:(DE-Juel1)127047
000014678 980__ $$aVDB
000014678 980__ $$aConvertedRecord
000014678 980__ $$ajournal
000014678 980__ $$aI:(DE-Juel1)INM-4-20090406
000014678 980__ $$aUNRESTRICTED
000014678 980__ $$aI:(DE-Juel1)INM-5-20090406
000014678 981__ $$aI:(DE-Juel1)INM-5-20090406